Rainbow Male and Female Cancer™ Test

  • Cancers caused by a single gene mutation - A comprehensive whole genome sequencing test for 100+ common and rare cancers.

  • Cancers caused by many small DNA changes - Breast, prostate and colon cancer polygenic risk scores (PRS).

  • Aggressive Prostate Cancer: Detects genes linked to aggressive prostate cancer that spreads rapidly to other parts of the body.

  • Invasive Breast Cancer: Help predict the chance of developing future breast cancer in women who have had early-stage (non-invasive) breast cancers.

Who is this test for:

  • Patients with a family history

  • Patients with no family history but worry about early signs of cancers

  • Individuals who had a gene test previously but with no findings

Introduction

Some people inherit genetic changes from their parents that increase their risk of developing cancer. Some mutations raise cancer risk a lot, while others have a smaller effect.

  • For women: About 3-5% of breast and colon cancers and up to 15% of ovarian cancers are linked to inherited genes.

  • For men: Prostate cancer risk is higher if it runs in the family. Men with a family history, especially a brother or a younger relative with prostate cancer, have a higher risk.

for Cancer Prevention

This test provides a comprehensive view of cancer risks and genetic factors, helping patients and their families make informed decisions about prevention and treatment.

  • Large DNA Changes: We use cutting-edge methods to find these changes (called large genomic rearrangement), often tied to early-onset cancers (before age 40).

  • Comprehensive Screening: Whole exome sequencing checks for mutations in many genes, covering more conditions than standard cancer tests.

  • New Discoveries: Whole genome sequencing includes newly identified cancer genes for thorough results.

  • RNA Testing: RNA sequencing confirms certain mutations and helps explain how genetic changes might lead to disease.

All tests are done in certified labs to ensure accuracy.

Cancer Prevention benefits

1. Prevent Hereditary Cancers

  • Genetic testing can reveal if you’re at higher risk for certain cancers, which can often be managed through monitoring, preventive medications, or even surgery.

  • Family members of an individual who carries a pathogenic cancer mutation may also consider testing to clarify their own risk.  

2. Get Guided Treatments

Knowing a genetic mutation can help doctors personalize treatments, such as:

  • Prostate cancer: Using the drug Olaparib (Lynparza) for specific genetic mutations.

  • Colorectal cancer: Considering colectomy for patients with Lynch syndrome.

  • Ovarian cancer: Using PARP inhibitors for BRCA1/2 mutations.

  • Breast cancer: Avoiding radiation for those with TP53 mutations.

3. Avoid Common Cancers

  • Many cancers, like lung and liver cancer, result from a mix of genetic changes and environmental factors. Whole genome sequencing helps assess genetic risk for these common cancers, and help you improve your diet and nutrition to prevent these cancers.

  • Talk to your doctor about testing options to help guide your care.

Comprehensive Test Details

Whole Genome Sequencing

This test is designed for both cancer patients and healthy individuals with or without symptoms or a family history of cancer.

  • What It Detects:

    Most cancer genetic tests miss certain large and microscopic DNA changes linked to early, severe cancers because they require advanced technology to detect. Without these, patients may get false-negative results. This test covers these challenging genes and mutations:

    • Mutations in hundreds of genes linked to hereditary cancers and cancer-causing genetic disorders.

    • Variants in 758 genes related to 100s of hereditary cancers and over 1000 diseases that can cause cancers.

    • Detailed analysis of copy number changes, splice, intronic and mosaic variants.

    • Chinese, European and mixed-race polygenic risk scores that provide additional risk information.

  • Who It’s For:

    • Cancer patients looking for personalized genetic insights.

    • Healthy individuals who want to understand their hereditary cancer risks, especially those with family members who carry known cancer-related gene mutations.

  • Advanced Features:

    • Large Genomic Rearrangements (LGRs): These changes, often linked to early-onset and severe cancers, are hard to detect but are included in this test.

    • Optional RNA Sequencing: Adds extra accuracy for detecting complex splicing changes that DNA tests might miss.

  • Optional Common Cancer Risk Assessment Test. Your sample can also be analyzed for Asian-based, polygenic risk assessment of seven common cancers (see list below).

  • 1. Breast

    2. Ovarian

    3. Colorectal

    4. Lung

    5. Prostate

    6. Uterine

    7. Gastric

    8. Pancreatic

    9. Thyroid

    10. Melanoma

    11. Renal

    12. Urinary Track

    13. Central & Peripheral Nervous System Cancers

    14. Paraganglioma

    15. Pheochromocytoma

    16. Brain

    17. Sarcoma

    18. Neuroendocrine

    19. Leukemia

    20. Myelodysplastic Syndrome

  • Lung, Bladder, Thyroid, Testicular, Esophageal, Kidney & Liver Cancers.

    • Ataxia-telangiectasia (A-T). Bloom syndrome. Carney complex.

    • Multiple endocrine neoplasia type 1, Type 2 (MEN1, MEN2). Costello syndrome.

    • Cowden and Cowden-like syndrome.

    • DICER1 syndrome. Dyskeratosis congenita. Neurofibromatosis type 2 (NF2).

    • Neurofibromatosis type 1 (NF1).

    • Familial acute myeloid leukemia (AML) syndrome. Nevoid basal cell carcinoma – also known as Gorlin syndrome.

    • Familial adenomatous polyposis (FAP). Nijmegen breakage syndrome (NBS).

    • Familial gastrointestinal stromal tumors (GIST). Oligodontia-colorectal cancer syndrome.

    • Familial neuroblastoma. Hereditary paraganglioma-pheochromocytoma.

    • Familial platelet disorder with propensity to myeloid malignancy (FPD/AML)

    • Perlman syndrome. GATA2 deficiency. Peutz-Jeghers syndrome (PJS)

    • Retinoblastoma.

    • Rhabdoid tumor predisposition syndrome (RTPS). Hereditary Lung Cancer

    • Simpson-Golabi-Behmel syndrome (SGBS). Hereditary papillary renal cell carcinoma.

    • Tuberous sclerosis complex (TSC). Hereditary paraganglioma-pheochromocytoma syndrome (PGL/PCC).

    • von Hippel-Lindau syndrome (VHL). Juvenile polyposis syndrome (JPS).

    • Werner syndromeLi-Fraumeni syndrome (LFS). Wilms tumor-related conditions

Why Rainbow’s Cancer Test ?

This whole genome sequencing test includes recently discovered gene variants that are not typically covered in standard tests.

  • We are one of the first in Asia to offer cancer polygenic risk scoring for Asians and Europeans.

  • It also carefully reviews gene variants specific to Asian populations, which are often not well-documented or have conflicting information in international databases.

  • Rainbow's expert teams from the U.S., Israel, and the U.K. work together to analyze these variants, leading to more accurate results for Asian, Caucasian, and mixed-race patients compared to other reports.

  • Families can also request an expanded report that covers additional health conditions or symptoms, not just cancers.

Is This Test Right For Me?

This test may be suitable for:

  • Patients showing cancer symptoms or complex health issues that may be linked to hereditary cancers.

  • Healthy people, especially relatives of cancer patients who have a known gene mutation, to understand their own risk.

  • People with a family history of cancer, suggesting a possible inherited risk.

  • Individuals with multiple close relatives who have had the same type of cancer.

References

For Physicians

  • Implications of Testing for Initial Management (for Patients with Newly-Diagnosed Cancers) & Testing at Decision Points in Treatment (ASCO)

  • Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616-624.

  • Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach. Human Genomics (2015) 9:12

  • Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol. 2016 March; 140(3): 565–574.

  • BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. GeneReviews® - NCBI Bookshelf. Last Update: December 15, 2016.

  • Hereditary Breast Cancer in the Han Chinese Population. J Epidemiol 2013;23(2):75-84

Web Resources

We provide free referrals to physicians with substantial clinical genetic experience for pre- and post-test consultation.

Contact Us for More Information